TRV GP IV, LLC
- SEC CIK
- 0001688325
- Latest filing
- Aug 7, 2026
Holdings in Q1 2021
Holdings as of Mar 31, 2021, filed May 12, 2021. Long positions only.
- Positions
- 4
- No 13F data for Q4 2020
- Portfolio value
- $271.4M
- No 13F data for Q4 2020
Livermore's 13F data starts with Q1 2021, so this quarter has no previous quarter to compare with and changes are not shown.
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DNTHDianthus Therapeutics, Inc. | COM | 8,008,204 | $94.8M | 34.9% | – | – | History |
| PLRXPliant Therapeutics, Inc. | COM | 2,132,867 | $83.9M | 30.9% | – | – | History |
| RVMDRevolution Medicines, Inc. | COM | 1,419,900 | $65.1M | 24.0% | – | – | History |
| FULCFulcrum Therapeutics, Inc. | COM | 2,343,154 | $27.6M | 10.2% | – | – | History |